279 related articles for article (PubMed ID: 34503126)
1. Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
Lin PC; Yeh YM; Hsu HP; Chan RH; Lin BW; Chen PC; Pan CC; Hsu KF; Hsiao JR; Shan YS; Shen MR
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503126
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
4. Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease-Associated Colorectal Cancers.
Din S; Wong K; Mueller MF; Oniscu A; Hewinson J; Black CJ; Miller ML; Jiménez-Sánchez A; Rabbie R; Rashid M; Satsangi J; Adams DJ; Arends MJ
Clin Cancer Res; 2018 Oct; 24(20):5133-5142. PubMed ID: 29950348
[No Abstract] [Full Text] [Related]
5. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
6. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.
McCord M; Steffens A; Javier R; Kam KL; McCortney K; Horbinski C
Acta Neuropathol Commun; 2020 Feb; 8(1):15. PubMed ID: 32051040
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden.
Yuan H; Ji J; Shi M; Shi Y; Liu J; Wu J; Yang C; Xi W; Li Q; Zhu W; Li J; Gong X; Zhang J
Front Oncol; 2021; 11():682017. PubMed ID: 33968789
[TBL] [Abstract][Full Text] [Related]
9. Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.
Ritch E; Fu SYF; Herberts C; Wang G; Warner EW; Schönlau E; Taavitsainen S; Murtha AJ; Vandekerkhove G; Beja K; Loktionova Y; Khalaf D; Fazli L; Kushnir I; Ferrario C; Hotte S; Annala M; Chi KN; Wyatt AW
Clin Cancer Res; 2020 Mar; 26(5):1114-1125. PubMed ID: 31744831
[TBL] [Abstract][Full Text] [Related]
10. Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy.
Lin PC; Yeh YM; Chan RH; Lin BW; Chen PC; Pan CC; Shen MR
BMC Cancer; 2021 Mar; 21(1):217. PubMed ID: 33653301
[TBL] [Abstract][Full Text] [Related]
11. Cancer mutational signatures identification in clinical assays using neural embedding-based representations.
Yaacov A; Ben Cohen G; Landau J; Hope T; Simon I; Rosenberg S
Cell Rep Med; 2024 Jun; ():101608. PubMed ID: 38866015
[TBL] [Abstract][Full Text] [Related]
12. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
Gatto L; Franceschi E; Tosoni A; Nunno VD; Bartolini S; Brandes AA
Immunotherapy; 2022 Jul; 14(10):799-813. PubMed ID: 35670093
[TBL] [Abstract][Full Text] [Related]
13. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
Natesan D; Zhang L; Martell HJ; Jindal T; Devine P; Stohr B; Espinosa-Mendez C; Grenert J; Van Ziffle J; Joseph N; Umetsu S; Onodera C; Turski M; Chan E; Desai A; Aggarwal R; Wong A; Porten S; Chou J; Friedlander T; Fong L; Small EJ; Sweet-Cordero A; Koshkin VS
Front Oncol; 2022; 12():816706. PubMed ID: 35321431
[TBL] [Abstract][Full Text] [Related]
14. Clinical and genomic characterization of mutational signatures across human cancers.
Liao J; Bai J; Pan T; Zou H; Gao Y; Guo J; Xu Q; Xu J; Li Y; Li X
Int J Cancer; 2023 Apr; 152(8):1613-1629. PubMed ID: 36533638
[TBL] [Abstract][Full Text] [Related]
15. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
16. A novel 4-gene prognostic signature for hypermutated colorectal cancer.
Ge W; Cai W; Bai R; Hu W; Wu D; Zheng S; Hu H
Cancer Manag Res; 2019; 11():1985-1996. PubMed ID: 30881123
[TBL] [Abstract][Full Text] [Related]
17. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
18. Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy.
Chen HZ; Bonneville R; Yu L; Wing MR; Reeser JW; Krook MA; Miya J; Samorodnitsky E; Smith A; Martin D; Dao T; Guo Q; Liebner D; Freud AG; Allenby P; Roychowdhury S
Oncotarget; 2019 Jan; 10(3):277-288. PubMed ID: 30719225
[TBL] [Abstract][Full Text] [Related]
19. Hypermutation and microsatellite instability in gastrointestinal cancers.
Yuza K; Nagahashi M; Watanabe S; Takabe K; Wakai T
Oncotarget; 2017 Dec; 8(67):112103-112115. PubMed ID: 29340115
[TBL] [Abstract][Full Text] [Related]
20. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]